Roche posts solid results ahead of looming patent cliff
Roche posts solid results ahead of looming patent cliff
Roche
Biopharmaceutical company - Diagnostics
Company Info
Recent News
Roche builds blockbuster case in MS as FDA decision approaches
Roche builds blockbuster case in MS as FDA decision approaches
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
Roche pauses future Germany investments
Amid tensions over government healthcare cost-cutting policies, Roche has slammed the brakes on new investments in Germany, joining an expanding group of drugmakers pulling back from the European country.
Roche returns to China’s Hansoh for $15B biobucks ADC pact
A year after their first antibody-drug conjugate team-up, Roche has returned to Hansoh Pharmaceutical for a mammoth $15 billion biobucks pact.
FDA clears Roche's Enspryng for thyroid eye disease
Roche has claimed US approval for Enspryng in a second indication, thyroid eye disease, that makes it a rival to drugs from Amgen and Viridian.
Roche adds another obesity drug with $1.16bn Rona deal
Roche has added to its weight-loss pipeline again, licensing an RNAi candidate targeting ALK7 from China's Rona Therapeutics in a deal worth up to $1.16 billion.
Roche breast cancer drug Itovebi turned down by NICE
NICE turned down NHS use of Roche's breast cancer drug Itovebi, which the company says reveals a flaw in the appraisal of combination therapies.
Roche extends China deal streak with $1B pact for RNAi obesity drug
An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.
Roche expands obesity R&D footprint with Rona deal worth $1B+
Roche has added another obesity drug candidate, licensing an asset from China-based RNAi developer Rona Therapeutics in a deal valued at roughly $1.16 billion. It is the latest in a string of China-focused licensing pacts for the Swiss pharma as it builds out its metabolic pipeline.
Roche sets sights on FDA approval decision of July 2027 with updated eye drug data
Roche has shared updated phase 3 data for its eye disease candidate a year on from a mixed readout, with authorities in the U.S., China, the EU and Japan reviewing filings and an FDA approval decision expected in July 2027.
Genentech opens its history books in 50 year anniversary doc
Fifty years ago, Herbert Boyer, Ph.D. and venture capitalist Robert Swanson met for drinks. | Known as the 'original biotech,' Genentech is unlocking its archives to shine light on its past, present and future in a new documentary celebrating its 50 year anniversary.
FDA starts review of Roche's multiple sclerosis pill
The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Roche culls myostatin candidate from obesity pipeline
Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.
Roche's Gazyva secures FDA nod in 2nd autoimmune indication
Roche's Gazyva secures FDA nod in 2nd autoimmune indication
Roche kidney drug's Phase 3 win sets up path to accelerated approval
Roche moves closer to entering an increasingly crowded kidney disease market where Novartis, Calliditas, Travere, Otsuka and Vera already have approved drugs.
Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
Roche turns to Dualitas to find new bispecific approaches for immunology
Roche turns to Dualitas to find new bispecific approaches for immunology
Roche sweeps neurology corporate reputation rankings once again
Roche sweeps neurology corporate reputation rankings once again
Roche taps Simcere for autoimmune trispecific for $1.53bn
Article from Pharmaphorum about Roche taps Simcere for autoimmune trispecific for $1.53bn.
Why Roche is 'really excited' about UCN2's obesity potential
Why Roche is 'really excited' about UCN2's obesity potential
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Roche bets $1B+ on DualityBio's ADC tech to tackle payload resistance
Roche bets $1B+ on DualityBio's ADC tech to tackle payload resistance
Roche-Hanmi, Akeso, a congressman's concerns—Fierce Pharma Asia
Roche-Hanmi, Akeso, a congressman's concerns—Fierce Pharma Asia
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
Roche's Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
Roche's Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
Roche drops lupus TCE, retains autoimmune cell therapy interest
Roche drops its lupus T-cell engager program but retains broader autoimmune cell therapy ambitions following pipeline review.
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add M&A
Roche CEO Schinecker says the company's late-stage pipeline is "so full" he's not feeling pressure to pursue major M&A.
Roche KRAS drug succeeds in head-to-head lung cancer study
Roche KRAS drug succeeds in head-to-head lung cancer study (reported by BioPharma Dive)
Roche orchestrates phase 3 lung cancer win over Amgen and BMS
Roche orchestrates phase 3 lung cancer win over Amgen and BMS — Fierce Biotech coverage of biopharma industry developments.
Roche tops cancer reputation rankings as AstraZeneca climbs back
Roche tops cancer reputation rankings as AstraZeneca climbs back. (Fierce Pharma.)
With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs
With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs — MedCity News coverage of biopharma industry developments.